The Israeli Ministry of Health has approved a request from Pluristem Therapeutics (NASDAQ:PSTI) to seek a regulatory nod to use its PLX cell therapy to treat COVID-19 on a per-patient compassionate use basis in Israel.
The company is proposing to use PLX to treat
severe pneumonia associated with COVID-19 and preventing the
deterioration to acute respiratory distress syndrome and sepsis.
Results from animal studies showed a therapeutic
benefit from PLX in pulmonary hypertension, lung fibrosis, acute kidney
injury and gastrointestinal injury, all potential complications from
SARS-CoV-2 infection.
It has not yet submitted a request for a specific patient.
https://seekingalpha.com/news/3552487-pluristem-up-13-premarket-on-use-of-plx-cells-to-treat-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.